Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated March 1, 2024, serves as a notification of the publication of the company's Annual Report for the fiscal year ended December 31, 2023. The filing confirms compliance with UK Financial Conduct Authority (FCA) Listing Rule 9.6.1R and Disclosure and Transparency Rules (DTRs).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural announcement directing investors to the full Annual Report 2023 for detailed financial data.
Material Changes
No material financial changes or comparative period analysis are included in this specific filing text. The document focuses solely on the availability of the Annual Report and the upcoming Annual General Meeting (AGM).
Guidance, Outlook, and Management Commentary
- Annual Report Availability: The Annual Report 2023 is available on the company website (www.annualreport.gsk.com) and has been submitted to the FCA's National Storage Mechanism (NSM).
- Shareholder Communications: Hard copies of the Annual Report and the Notice of Annual General Meeting 2024 will be mailed to shareholders electing paper communications on or around March 25, 2024.
- AGM Notice: The AGM Notice will be made available to non-paper shareholders on the same date.
- Disclaimer: The filing explicitly states it is not a substitute for reading the full Annual Report.
Investor Verification Checklist
- Verify the full financial results for the year ended December 31, 2023, by accessing the Annual Report 2023 on the GSK website or the FCA NSM.
- Confirm the date and agenda of the 2024 Annual General Meeting via the AGM Notice.
- Review the unedited full text of media communications included within the Annual Report 2023 as required by DTRs.